Navigation Links
George Institute receives Gates Foundation grant to survey funding flows
Date:3/20/2008

A team of international health experts is launching a major study to track global funding for research and development (R&D) for neglected diseases in developing countries by surveying global public, private and philanthropic investments. As funding for R&D for neglected diseases has increased, donors do not have a complete overview of how much is currently being spent and on what diseases, which makes determining funding gaps difficult. The George Institute for International Health received a 5 year $US8.8 million grant from the Bill & Melinda Gates Foundation to collect and report global investment into R&D for neglected diseases.

Too often, global health funders must base substantial R&D investment decisions on out-of-date, unreliable information. They lack information about how much or where to invest, or how their investments sit in the context of overall funding flows and priorities, said Dr Mary Moran, Project Leader at the George Institute. By providing an updated and in depth overview, we hope to help donors around the world determine where their investments are most needed, and prevent duplication of effort she added.

Annually for a five year period, The George Institute will survey and analyse public and private global funders, intermediaries and developers, collecting data through an online survey. The survey will examine all aspects of product R&D funding from basic research, through discovery and development, to post-registration activities that support product introduction. It will measure R&D investment into new drugs, vaccines, diagnostics, microbicides and other tools for tropical diseases such as malaria and sleeping sickness, as well as developing-country strains of global diseases such as pneumonia, meningitis and HIV/AIDS, which are often overlooked by product developers that typically prioritize industrialized country markets.

We hope that better information about global funding for R&D for neglected disea
'/>"/>

Contact: Emma Orpilla
eorpilla@thegeorgeinstitute.org
61-299-934-592
Research Australia
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Mothers Know Best: NFL Moms Team With Eddie George to Showcase a Better Way to a Healthier Lifestyle
2. Live Webcast With President George H.W. Bush as Bono and DATA Are Honored With National Constitution Centers 2007 Liberty Medal in Historic Philadelphia
3. President George W. Bush Appoints Susan G. Komen for the Cure Founder as Chief of Protocol
4. George Mason University professor receives $2.6 million NIH grant to study Alzheimers disease
5. New USAID grant helps Georgetown meet unmet family planning needs worldwide
6. CNS Response, Inc. Appoints George C. Carpenter IV to Position of President
7. Reunion with patient inspires follow-up study on treatment for DiGeorge syndrome
8. Georgetown leads major effort to combat disparities in DC stroke care
9. Skinvisible Appoints Dr. George Korkos to Its Advisory Board
10. George Harrison Fund for UNICEF Announces Donation for Bangladesh Cyclone Relief
11. DaVita Nurse Gives Keynote Speech to St. Georges Hospital Vascular Access Annual Meeting in London
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...- The Providence Service,Corporation (Nasdaq: P...mpany,s,Chief Operating Officer, has been appoint...is, appointment fills the vacancy left by the Apri...rns the board to six members. Mr.,Norris will no.... Norris, age 41, has been with Providence since i...
(Date:11/21/2008)...ennox-Gastaut syndrome , , FRIDAY, Nov. ...ufinamide) has been approved as a supplementary tr...x-Gastaut syndrome, the U.S. Food and Drug Adminis...sed on results of a four-month clinical trial that...nts who took a placebo, those who took the drug ha...
(Date:11/21/2008)...re/ -- New research at West Virginia University ... product aimed at young adults is catching on. And...l Snus - touted as a socially acceptable way to sa...s of nicotine. , , "Camel Snus contains mor...ruce Adkins of the state Division of Tobacco Preve...
(Date:11/21/2008)... -- U.S. News & World Report and the National ...Choice(R) HealthPlan of South Carolina in the top ...d in U.S. News & World Report,s issue this wee...he nation,s best health plans based on clinical qu...scores. NCQA and U.S. News & World Report rank...
Breaking Medicine News(10 mins):Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 2Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 3Health News:FDA Approves New Drug for Severe Epilepsy 2Health News:Experts Say New Tobacco Product Targets Young Adults 2Health News:Experts Say New Tobacco Product Targets Young Adults 3Health News:BlueChoice HealthPlan Ranks in Top Third of America's Best Health Plans 2
...u.s., mothers who breastfed their babies in public... act was made to prove that breastfeeding was an a...h mother and child. The U.S. Healthy People 2010 ...n of mothers who choose to breastfeed their babies...
... National Institutes of Health (NIH) and the Cente...oday that more than one-third of adults having dia...abetes in adults aged 20 and older has increased f...period between 1988 to 1994 and 1999 to 2002. How...
...ervations on one side and on the other side increa... does not suffer is the UPA Government’s please-a...eft supporters announced that 27 per cent of the s...ns would be available to Other Backward Classes (O...
...une diseases, named Juvenile rheumatoid arthritis ...which inversely affect health-related quality of l...gests patient prognosis in adults – study finds. B...d. Arthritis Care & Research journal published a...
Other Medicine News:Health News:Breastfeeding Mothers Arrested For Public Indecency 2Health News:Undetected Cases Of Diabetes Boom In The US 2Health News:Undetected Cases Of Diabetes Boom In The US 3Health News:Undetected Cases Of Diabetes Boom In The US 4Health News:The Government’s Balancing Act on Reservatio 2Health News:The Government’s Balancing Act on Reservatio 3Health News:Socioeconomic Status Plays A Role In Juvenile Rheumatoid Arthritis 2
(Date:11/20/2008)...wire/ -- Epeius Biotechnologies,announced today t... in,chemotherapy-resistant metastatic soft tissue...nt P. Chawla, principal investigator, at the CTOS ...r 13-15, 2008. Patients received,repeated infusio...nalysis of,safety and efficacy data showed no maj...
(Date:11/20/2008)...20 Arpida (SWX:,ARPN) a...ory Committee of the,U.S. Food and Drug Administr...l of intravenous iclaprim, an antibiotic currently...h complicated skin and skin structure infections,...sistant Staphylococcus,aureus (MRSA). , Ar...
(Date:11/20/2008)...linical data from a prospective,registry presente...ws DVT,treatment with the Trellis(R) Peripheral I... Clara, CA) successfully breaks up the blood clot ...is technique, called isolated pharmacomechanical t... safely than current catheter-directed thrombolysi...
(Date:11/19/2008)...tatistical significance , , ISELIN, N.J., N...ion (Nasdaq: PARS ) today announced results from...ulsion (NE) drug delivery technology formulated wi...lti-center, randomized, double-blinded, placebo-co...f the Company,s 3% Diclofenac Diethanolamine NanoE...
Breaking Medicine Technology:Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue Sarcoma and Osteosarcoma: Phase I/II & Confirmatory Phase II Studies 2Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 2Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 3Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 4Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 2Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 3Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream 2Off Hours Heart Patients Less Likely to Get Angioplasty 17343 1Off Hours Heart Patients Less Likely to Get Angioplasty 17343 2Analysis of RNA role in spreading disease advances study of damaging plant infections 2981 1Analysis of RNA role in spreading disease advances study of damaging plant infections 2981 2Analysis of RNA role in spreading disease advances study of damaging plant infections 2981 3Analysis of RNA role in spreading disease advances study of damaging plant infections 2981 4Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2008 Financial Results 4742 1Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2008 Financial Results 4742 2Crop management strategies key to a healthy Gulf planet 2980 1Crop management strategies key to a healthy Gulf planet 2980 2Crop management strategies key to a healthy Gulf planet 2980 3
...ong ADHD Patients Nearly Triple That,of General Po..., INDIANAPOLIS, May 23, 2007 /PRNewswire-FirstCall...ttera(R) (atomoxetine HCl),improved symptoms of At...patients with comorbid alcohol abuse disorder, sug... with Strattera in,patients with both disorders. R...
...ty Demonstrated Among Patients with,Active Disease... --,ChemoCentryx, Inc., a clinical-stage biopharma...g and commercializing,orally-administered therapeu...ata today from the company,s Phase 2 clinical tria...-inflammatory agent,that targets the chemokine rec...
Other Medicine Technology:Study Suggests Strattera Improved ADHD Symptoms in Patients With,Comorbid Alcohol Abuse 2Study Suggests Strattera Improved ADHD Symptoms in Patients With,Comorbid Alcohol Abuse 3Study Suggests Strattera Improved ADHD Symptoms in Patients With,Comorbid Alcohol Abuse 4Study Suggests Strattera Improved ADHD Symptoms in Patients With,Comorbid Alcohol Abuse 5Study Suggests Strattera Improved ADHD Symptoms in Patients With,Comorbid Alcohol Abuse 6ChemoCentryx Presents Positive Phase 2 Clinical Data for,Traficet-EN in Crohn's Disease at the Digestive Disease Week 2007,Conference 2ChemoCentryx Presents Positive Phase 2 Clinical Data for,Traficet-EN in Crohn's Disease at the Digestive Disease Week 2007,Conference 3ChemoCentryx Presents Positive Phase 2 Clinical Data for,Traficet-EN in Crohn's Disease at the Digestive Disease Week 2007,Conference 4ChemoCentryx Presents Positive Phase 2 Clinical Data for,Traficet-EN in Crohn's Disease at the Digestive Disease Week 2007,Conference 5
Ideal for chest procedures.
Male Compression Vests
Female Compression VEST w/sleeves
Male Support Brief
Medicine Products: